Fat loss has emerged as a poor prognostic factor in patients with advanced cancer independent of body weight ([@bib26]). However, the prognostic significance of adiposity, at the time of cancer diagnosis is not clear. The 'obesity paradox' refers to obese patients experiencing longer survival after a diagnosis of a disease and has been described in some wasting associated diseases such as cancer, cardiovascular disease, diabetes, and renal diseases (reviewed by [@bib30]). While some studies have shown an association between obesity and poor survival ([@bib21]; [@bib4]; [@bib5]; [@bib17]), others have reported obesity, compared to low or healthy body mass index (BMI, kg m^−2^), to be associated with lower mortality after a cancer diagnosis ([@bib12]; [@bib14]; [@bib20]; [@bib32]). Previous studies addressing the obesity paradox have primarily used BMI as an assessment of body composition. BMI does not provide an appropriate assessment of body composition as it does not differentiate between fat and fat-free mass or different fat depots. Adipose tissue and skeletal muscle are two major body compartments with different functions; therefore, the concept of the 'obesity paradox' needs to be investigated based on the independent prognostic significance of fat and muscle rather than the BMI. Moreover, individual variability in adiposity ([@bib27]), especially visceral adiposity ([@bib18]; [@bib16]) exists within each BMI category. Recently studies have applied computed tomography (CT) imaging to deal with the controversial concept of the obesity paradox. CT image analysis is an opportunistic method for body composition evaluation in an oncological population, due to CT imaging being a component of standard care ([@bib7]). CT image analysis enables precise quantification of adipose depots and muscle and has emerged as the gold standard for body composition assessment in cancer patients ([@bib8]). Visceral and subcutaneous adipose differ in anatomic location, endocrine function, adipokine secretion and lipolytic activity (reviewed previously ([@bib36]; [@bib15])). Variability in regional adipose tissue distribution by sex ([@bib36]) and within each category of BMI ([@bib18]; [@bib16]), as well as divergent behavior of adipose depots ([@bib36]; [@bib6]) demonstrates the need to understand the importance of visceral and subcutaneous adiposity in cancer survival.

Recently, [@bib20] reported that BMI ⩾25 kg m^−2^ in both sexes was associated with longer survival using sex-specific cutoffs in a large cohort of cancer patients. However, survival advantage of obesity was diminished in the presence of concurrent conditions including weight loss, sarcopenia (low muscle mass) and low muscle radiodensity (fat infiltrated muscle). Considering BMI limitations in predicting adiposity, sex-specific values associated with mortality for adipose tissue are required to evaluate the effect of low muscle mass on survival of high adiposity patients.

Studies assessing the effect of adiposity, either visceral or subcutaneous, on cancer survival have yielded inconsistent results ([@bib31]; [@bib10]; [@bib16]; [@bib19]). Small sample sizes, lack of cancer-specific cut offs associated with survival, exclusion of conventional or body composition variables associated with survival in multivariate analysis as well as focusing on short- or long-term mortality as an outcome contribute to inconsistent results. Previous studies have applied cut-offs derived from renal cell carcinoma patients in an Asian population ([@bib16]; [@bib19]) that may not be generalizable to all cancer populations or to non-Asians. Moreover, adipose tissue distribution differs by sex ([@bib36]), which demonstrates the need to apply sex-specific cut offs.

Considering the limitations of using BMI as an indicator of adiposity, an adiposity index is preferred. However, controversy remains regarding prognostic significance of adipose tissue in cancer, as adiposity cut-points associated with survival in cancer are unknown. The majority of previously published studies have used median or sex specific median to evaluate the association of adiposity with survival. However, sex-specific values that associate with survival are required. Lack of cut-offs characterise a major gap in the understanding of the relationship between adiposity and risk of death after a cancer diagnosis. We aimed to explore the independent prognostic significance of adipose tissue as well as the importance of visceral and subcutaneous adiposity in estimating cancer mortality in a large cohort of cancer patients. Survival advantage of adiposity in the presence and absence of sarcopenia was also evaluated. It was hypothesised that higher adiposity, especially subcutaneous adiposity, as defined by CT images would be associated with the lowest mortality risk in cancer patients, but that the presence of sarcopenia would diminish the survival advantage of high adiposity.

Materials and methods
=====================

Patients
--------

The study was performed in accordance with the institutional research ethics board. Alberta Cancer Board Research Ethics Board (Edmonton, Alberta, Canada) reviewed and approved this study. Our site encompasses patients in Northern Alberta, Canada. Data regarding cancer site, morphology, clinical and demographic characteristics for each of the subjects were collected from the Alberta Cancer Registry. We extracted data from gastrointestinal or respiratory cancer patients' initial visit to medical oncology before receiving any treatment, between January 2004 and January 2007 (*n*=1473). Patient's baseline characteristics for gastrointestinal and respiratory tract cancers were reported in detail in [@bib20]. CT scans for this study were taken within 30 days of patient's initial assessment. Metastatic renal cell carcinoma patients (*n*=273) treated with sunitinib between March 2005 and 2012 at the Cross Cancer Institute (Edmonton, Alberta, Canada) were also included in this study. For these patients, CTs within a median of 26 days (95% CI: 12--63 days) from the start of the treatment were used to represent baseline body composition. Self-reported height, weight and performance status (PS) were collected using the Patient-Generated Subjective Global Assessment.

CT image analysis
-----------------

All participants had body composition measured using secondary analysis of images retrieved from the patient clinical record. Total adipose tissue area measurement was conducted by analyzing CT scans at the third lumbar vertebra (L3). The third lumbar was selected as a standardised landmark, as adipose tissue areas in a single CT image at L3 correlate well with whole body fat mass ([@bib33]; [@bib25]). Regression equations for visceral adipose tissue have not been developed for cancer populations; however, visceral adipose tissue cross-sectional area at L3 strongly correlate with whole-body visceral adipose tissue volume in healthy populations ([@bib34]). Two consecutive transverse CT images extending from L3 to the iliac crest were assessed using Slice-O-Matic (V4.2; Tomovision, Montreal, QC, Canada). Adipose tissue cross-sectional areas were calculated by using standard Hounsfield Unit (HU) thresholds of −29 to 150 HU for skeletal muscle (SM), −150 to −50 HU for visceral adipose tissue ([@bib23]) and −190 to −30 HU for subcutaneous adipose tissue ([@bib24]). Tissue cross-sectional areas (cm^2^) were calculated by summing the given tissue pixels and multiplying by the pixel surface area. Mean tissue areas for two consecutive images were calculated; the mean CV of paired images was 2.7% for adipose tissue areas. Visceral and subcutaneous adipose tissues cross-sectional areas were summed to estimate total adipose tissue areas. The cross-sectional areas of skeletal muscle, total adipose tissue, visceral adipose tissue and subcutaneous adipose tissue were normalised for the patient height to calculate indexes (cm^2^ m^−2^) for skeletal muscle (SMI), total adipose tissue (TATI), visceral adipose tissue (VATI) and subcutaneous adipose tissue (SATI). Mean muscle radiation attenuation (HU) was reported as muscle radiodensity which correlates with triglyceride content of the muscle ([@bib2]).

Statistical analysis
--------------------

Descriptive statistics are presented as mean±s.d. for continuous variables and percentage for categorical variables. The comparison between study groups were conducted using independent *t*-test and Pearson *χ*^2^ test for continuous and categorical variables, respectively. Overall survival was defined as the time from diagnosis to the date of death or date of last contact of August 2010 for 1473 gastrointestinal and respiratory tract cancer patients. For 273 metastatic renal cell carcinoma patients, time from the start of sunitinib treatment to the date of death or date of last contact (March 2012) were defined as survival time. Patients alive at the time of the last contact were censored at the date last known to be alive. Univariate and multivariate analysis to determine mortality hazard ratios (HR) were conducted using Cox proportional hazard models to identify significant predictors of mortality. Variables significant at *P*\<0.10 level in the univariate analysis were selected to be entered in the multivariate model. Results were reported as HRs and 95% confidence intervals (CIs). Factors known to correlate with mortality of cancer patients ([@bib20]) including age, sex, cancer type, stage, performance status as well as body composition variables including lumbar skeletal muscle index, muscle radiodensity and TATI or VATI and SATI were included in the analysis.

Cut-off values for lumbar skeletal muscle index (SMI) and muscle radiodensity were derived from [@bib20] established cut-offs in gastrointestinal and respiratory cancer patients ([@bib20]). For SMI, values below 41 cm^2^ m^−2^ in females of all BMI categories and SMI values below 43 cm^2^ m^−2^ in males with a BMI \<25 and SMI \<53 cm^2^ m^−2^ in male with a BMI ⩾25 associated with shorter survival and were considered as sarcopenic groups. Muscle radiodensity of \<33 HU in patients with a BMI ⩾25 and \<41 in those with a BMI \<25 associated with shorter survival ([@bib20]).

Sex-specific adiposity values associated with the lowest mortality risk were determined by examining the continuous variable on the basis of quartiles using the first quartile as the reference group in an adjusted multivariate model. Following, adjunct quartiles with similar risk of death (non-statistically significant different HRs indicated by non-significant *P*-value in Cox model) were pooled together and statistically significant values that provide satisfactory discrimination of mortality risk between patients were determined for each sex. High adiposity, characterised by TATI ⩾107.7 cm^2^ m^−2^ in male and ⩾102.2 cm^2^ m^−2^ in females, were the values that associated with the lowest mortality risk ([Supplementary Tables S1A and S1B](#sup1){ref-type="supplementary-material"}). In order to find mortality associated values, VATI and SATI were separately divided into quartiles and in adjusted models, visceral adiposity of VATI of 52.9 cm^2^ m^−2^ in males and 51.5 cm^2^ m^−2^ in females were defined as VATI values that discriminate between high and low risk patients. SATI ⩾50 cm^2^ m^−2^ in males and ⩾42 cm^2^ m^−2^ in females, defined as high subcutaneous adiposity, were set as values associated with the lowest mortality. Following men and women were pooled together and using sex-specific values, the independent prognostic significant of adiposity were evaluated in whole population.

Kaplan--Meier curves were plotted to estimate survival over time and the log-rank test were used to compare the difference between high *vs* low adiposity survival curves. Pearson correlation test was conducted to assess whether there was a significant relationship between adiposity and muscle radiodensity. Analyses were performed using IBM SPSS Statistic Software 21 (SPSS for Windows, version 21.0, SPSS, Chicago, IL, USA). *P*-values \<0.05 was considered as a significant difference.

Results
=======

Patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The most common cancer was colorectal (42% of cancer types in both sexes) with the majority of patients in stage IV (62% in men and 59% in women). Patients were followed until death (*n*=1207) or censoring (the date last known to be alive; *n*=555). The median overall survival of the cohort was estimated to be 16.7 months (95% CI, 15.4--18.1) and the median follow-up of censored patients was 24.8 months (95% CI, 20.8--28.8). Fifty-three percent of the population were overweight or obese. Men had higher BMI and SMI than women ([Table 1](#tbl1){ref-type="table"}). Although TATI did not differ between males and females, fat distribution differed between sexes, with men having greater visceral adiposity and women having more subcutaneous fat ([Table 1](#tbl1){ref-type="table"}).

To evaluate the independent prognostic significance of adiposity in predicting mortality, an adjusted Cox proportional hazard analysis was performed. The following variables associated with mortality risk in patients: age, cancer type, stage, PS, TATI, SMI and muscle radiodensity in the univariate analysis ([Table 2](#tbl2){ref-type="table"}). Compared with the reference group with high adiposity, patients with low adiposity, had a significant increase in mortality risk after adjustment for major predictors of survival (HR: 1.26; 95% CI: 1.11--1.41; *P*\<0.001) ([Table 2](#tbl2){ref-type="table"}). Patients with high adiposity survived 19.8 months (95% CI, 17.6--22) while the median survival in low adiposity group was 14.0 months (95% CI, 12.4--15.6) (*P*=0.001).

In order to investigate the importance of fat depots in predicting cancer mortality, in the next step, multivariate analysis was repeated including all of the same variables presented in [Table 2](#tbl2){ref-type="table"} and VATI and SATI rather than TATI. In multivariate analysis, including both VATI and SATI, only subcutaneous adiposity significantly associated with survival ([Table 3A](#tbl3){ref-type="table"}). Compared to the high SATI group, low SATI was an independent predictor of increased mortality in multivariate analysis (HR: 1.26; 95% CI: 1.11--1.43; *P*\<0.001) ([Table 3A](#tbl3){ref-type="table"}). Subsequently, we used a Kaplan--Meier model to estimate survival probability based on subcutaneous adiposity, revealing longer median survival in patients with high SATI (19.3 months; 95% CI, 17.6--21.0) compared to the patients with low SATI (13.1 months; 95% CI, 11.4--14.7) ([Figure 1](#fig1){ref-type="fig"}; *P*\<0.001). The trend for high VATI patients to have a longer median survival time (19.7 months; 95% CI, 17.1--22.3) compared to those with a lower VATI (15.1 months; 95% CI, 13.6--16.5) was not significant ([Table 3A](#tbl3){ref-type="table"}; *P*=0.08).

To investigate the prognostic significance of different depots, patients were categorised into one of four phenotypes according to categories of high and low VATI and SATI ([Table 3B](#tbl3){ref-type="table"}). Having low SATI was associated with the shortest survival with the highest mortality risk. Patients with both high SATI and VATI had the best survival advantage with a median survival of 20.4 months ([Table 3B](#tbl3){ref-type="table"}). Therefore, the diminished survival in patients with high visceral adiposity concurrent with low subcutaneous adiposity suggests high visceral adiposity may not be protective alone and indicates the importance of high subcutaneous adiposity.

Low subcutaneous adiposity was more prevalent in male patients with low BMI ([Table 4](#tbl4){ref-type="table"}). No significant difference was observed between low and high SATI patients regarding cancer stage and performance status. Mean SMI was significantly higher in those with greater subcutaneous adiposity (48.1±10 cm^2^ m^−2^) compared to the low SATI group (45.8±8.6 cm^2^ m^−2^, *P*\<0.001) ([Table 4](#tbl4){ref-type="table"}). Despite having higher SMI, patients with high subcutaneous adiposity had significantly lower muscle radiodensity compared to the patients with low SATI (31.6±9.2 *vs* 38.7±8.4, *P*\<0.001) ([Table 4](#tbl4){ref-type="table"}). Among patients with high subcutaneous adiposity, 62% exhibited low muscle radiodensity. The association between adiposity and muscle radiodensity was investigated and a moderate, but highly significant, inverse association was observed between the muscle radiodensity, and visceral adipose adiposity (*r*=−0.43, *P*\<0.001) and subcutaneous adiposity (*r*=−0.44, *P*\<0.001).

We did not include weight loss in our model, as the data were not available for metastatic renal cell carcinoma patients. However, in subgroup analysis of 1176 respiratory tract and colorectal cancer patients for whom weight loss was available, we observed that adiposity remained as an independent predictor of mortality in the presence of weight loss. Low adiposity independently associated with elevated mortality risk (HR: 1.18; 95% CI: 1.01--1.37; *P*= 0.03) in a multivariate model adjusted for age, cancer type, stage, performance status, skeletal muscle index, muscle radiodensity and weight loss.

Presence of sarcopenia decreased the median survival within each 4-adiposity phenotypes ([Table 5](#tbl5){ref-type="table"}). However, no significant difference in median survival was observed between sarcopenic and non-sarcopenic patients with concurrent high visceral and subcutaneous adiposity. The shortest median survival was observed in patients with a low VATI and SATI regardless of whether patients were sarcopenic or not. The effect of sarcopenia, however, was more pronounced in patients with low SATI. Therefore, in the presence of sarcopenia, the longest survival was observed in patients with high subcutaneous adiposity.

Discussion
==========

In this large, retrospective cohort study investigating the prognostic significance of adiposity in cancer mortality, low adiposity was as an independent predictor of mortality risk and shorter survival after adjusting for known prognostic variables including age, cancer type, stage, performance status, skeletal muscle index and muscle radiodensity. To our knowledge, this is the largest study assessing the association between adipose depots and cancer mortality. To determine whether different adipose depots, visceral or subcutaneous, associated with mortality risk in cancer patients, two different measures of adiposity, VATI and SATI were included in multivariate analysis. Our data demonstrate that cancer patients with lower subcutaneous adiposity are at greater risk of mortality and that patients with a high SATI experienced a significantly longer median survival time compared to those with a lower SATI. Moreover, having high VATI, without high subcutaneous adiposity increases mortality risk. This result is consistent with Antoun *et al* who reported that a high amount of subcutaneous adipose tissue independently and significantly associates with longer survival in 120 prostate cancer patients ([@bib1]). Controversy remains regarding the association between visceral adiposity and cancer survival as visceral adipose tissue is reported to be associated with poorer survival in patients with hepatocellular carcinoma ([@bib10]) or with better prognosis ([@bib16]; [@bib19]) in advanced renal cell carcinomas. Adiposity variables such as visceral to subcutaneous adipose tissue ratio have been applied in previous studies ([@bib10]).

Visceral and subcutaneous adipose tissue distribution differs between males and females. These depots are also metabolically different as visceral adipose tissue produces more inflammatory cytokines such as interleukin 6, tumour necrosis factor alpha and other adipokines ([@bib9]; [@bib13]). Higher responsiveness of visceral adipose tissue to lipolytic factors as well as direct delivery of adipokines and free fatty acids to the liver links visceral adipose tissue to a pro-inflammatory state that can affect liver metabolism and whole body homeostasis ([@bib11]). Subcutaneous adipose tissue, on the other hand, is the main producer of leptin ([@bib6]) that exerts some metabolic benefits on insulin sensitivity, glucose and lipid metabolism ([@bib35]; [@bib29]). These metabolic differences demonstrate the necessity to evaluate cancer mortality based on visceral and subcutaneous adiposity rather than total adiposity.

Potential explanations for the protective effects of high adiposity have not been clearly identified. Excess adipose tissue in obese cancer patients may provide fuel to bridge the gap between decreased energy intake and elevated requirements as hypothesised by [@bib14]. Obese patients may frequently undergo routine medical care and therefore be diagnosed at earlier stages (reviewed by [@bib30]). Signals produced by adipose tissue, such as leptin, associates with better prognosis and longer survival in colorectal cancer patients ([@bib28]). Lower mRNA expression of fatty acid synthase and acetyl-CoA carboxylase, enzymes involved in fatty acid production as an energy substrate, have been observed in the tumour of obese renal cell carcinoma patients ([@bib12]).

There was a moderate but highly significant inverse association between muscle radiodensity and adiposity in this study. Fat accumulation in the muscle (low muscle radiodensity) might be related to the various factors such as elevated transportation and uptake of fatty acid into muscle or increased availability of lipids ([@bib22]). On the other hand, enlarged fat mass associates with elevated release of fatty acids which might be considered as one of the potential sources contributing to the low muscle radiodensity ([@bib3]). Although low adiposity and low muscle radiodensity were both independent predictors of mortality in this study, it may be appropriate to undertake further statistical analysis in order to assess the effect of various interactions between muscle radiodensity with adiposity on the survival of cancer patients.

We acknowledge various limitations of the present study. Although adiposity independently associates with mortality risk, the majority of patients were in Stage IV of their disease; therefore, results may not be generalised to the cancer patients in earlier stages of cancer. Lack of treatment data was also a limitation; however, data for all cancer types, except metastatic renal cell carcinoma patients, were collected during patients' first visit to medical oncology before undergoing any cancer treatment. Stage IV metastatic renal cell carcinoma patients are administrated sunitinib immediately after diagnosis, as part of standard care, and CTs for these patients were taken within a median of 26 days from the start of the treatment which is not a sufficient amount of time to change body composition from baseline. Lastly, the retrospective nature of this study limits assessment of various metabolic characteristics such as insulin resistance and inflammation in high and low adiposity patients.

In conclusion, lower adiposity independently associates with increased mortality risk after adjustment for major predictors of mortality in cancer patients. Among adipose tissue depots, subcutaneous adipose tissue appears to hold prognostic value over visceral adipose. When a combination of adiposity and sarcopenia was considered, presence of sarcopenia associated with shorter survival in all adiposity cancer patients. However, effect of sarcopenia on survival was more pronounced in patients with low subcutaneous adiposity. Therefore, high adiposity in the absence of sarcopenia appears to be a protective body composition phenotype, and associates with a survival advantage. Interventions to promote muscle anabolism and maintain adipose tissue should be considered in clinical settings to improve survival of cancer patients.
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###### 

Click here for additional data file.

![**Kaplan--meier survival curves in patients with high *vs* low subcutaneous adiposity.** Kaplan--Meier curves were plotted to estimate survival over time and the log-rank test were used to compare the difference between survival curves. Longer median survival was observed in patients with high subcutaneous adiposity compared to the patients with low subcutaneous adiposity (*P*\<0.001).](bjc2017149f1){#fig1}

###### Patient characteristics by sex at baseline

                                            **Male (*****n*****=1047)**   **Female (*****n*****=715)**    
  ----------------------------------------- ----------------------------- ------------------------------ ------------------------------------
  Age, years                                                                                              
   Mean±s.d.                                64.4±11.0                     64.6±11.3                      0.8[a](#t1-fn3){ref-type="fn"}
  Cancer site                                                                                            \<0.001[b](#t1-fn4){ref-type="fn"}
   Colon/rectum                             439 (42)                      301 (42)                        
   Respiratory tract                        229 (22)                      207 (29)                        
   Pancreas                                 69 (7)                        75 (10)                         
   Esophageal                               16 (1)                        7 (1)                           
   Stomach                                  33 (3)                        18 (3)                          
   Other GI                                 18 (2)                        19 (3)                          
   Kidney                                   243 (23)                      88 (12)                         
  Cancer stage                                                                                           0.22[b](#t1-fn4){ref-type="fn"}
   I                                        35 (3)                        35 (5)                          
   II                                       134 (13)                      88 (12)                         
   III                                      224 (21)                      169 (24)                        
   IV                                       654 (63)                      423 (59)                        
  ECOG PS                                                                                                0.72[b](#t1-fn4){ref-type="fn"}
   0                                        201 (19)                      139 (19)                        
   1                                        468 (45)                      313 (44)                        
   2                                        207 (20)                      133 (19)                        
   3                                        158 (15)                      115 (16)                        
   4                                        13(1)                         14 (2)                          
  BMI, kg m^−2^                             26.3±4.7                      25.3±5.9                       \<0.001[a](#t1-fn3){ref-type="fn"}
  BMI category, kg m^−2^                                                                                 \<0.001[b](#t1-fn4){ref-type="fn"}
   \<20.0                                   72 (7)                        124 (18)                        
   20.0--24.9                               356 (35)                      263 (37)                        
   25.0--29.9                               406 (39)                      184 (26)                        
   ⩾30.0                                    195 (19)                      134 (19)                        
  Skeletal muscle index, cm^2^ m^−2^        51.4±8.7                      41.1±7.0                       \<0.001[a](#t1-fn3){ref-type="fn"}
  Muscle radiodensity, HU                   34.7±9.0                      34.0±10.2                      0.12[a](#t1-fn3){ref-type="fn"}
  Total adipose index, cm^2^ m^−2^          111.3±59.1                    112.6±72.7                     0.69[a](#t1-fn3){ref-type="fn"}
  Visceral adipose index, cm^2^ m^−2^       57.0±36.4                     34.6±27.6                      \<0.001[a](#t1-fn3){ref-type="fn"}
  Subcutaneous adipose index, cm^2^ m^−2^   54.3±29.7                     77.9±50.3                      \<0.001[a](#t1-fn3){ref-type="fn"}

Abbreviations: BMI=body mass index; ECOG PS=Eastern Cooperative Oncology Group performance status; GI=gastrointestinal; HU=Hounsfield unit; s.d.=standard deviation.

Continuous variables are presented as mean±s.d.

Independent *t*-test for continuous variables.

Pearson *χ*^2^ test for categorical variables comparison.

###### Median survival, univariate and multivariate analysis by conventional and body composition parameters for overall mortality

                                                         **Univariate**      **Multivariate**                        
  --------------------- ------ ----- ------------------- ------------------- ------------------ -------------------- ---------
  Sex                                                                                                                 
   Female               715    482   15.6 (13.7--17.5)                                                                
   Male                 1047   725   17.2 (15.3--19.0)   1.10 (0.95--1.20)   0.27                                     
  Age, years                                             1.01(1.00--1.01)    \<0.001            1.008(1.002--1.01)   0.01
  Cancer site                                                                                                         
   Colon/rectum         740    358   30.7 (27.5--33.9)                                                                
   Respiratory tract    436    383   9.4 (7.7--11.2)     2.83 (2.44--3.27)   \<0.001            2.59 (2.23--3.01)    \<0.001
   Pancreas             144    126   5.4 (3.8--7.0)      3.94 (3.21--4.84)   \<0.001            3.16 (2.58--3.93)    \<0.001
   Esophageal           23     16    17.5 (9.6--25.5)    1.93 (1.17--3.18)   \<0.001            1.80 (1.09--2.98)    0.02
   Stomach              51     41    11.3 (6.7--16.0)    2.46 (1.78--3.40)   \<0.001            2.20 (1.59--3.05)    \<0.001
   Other GI             37     23    20.6 (3.4--37.8)    1.59 (1.04--2.42)   0.03               1.46 (0.96--2.23)    0.08
   Kidney               331    260   17.7 (14.4--21.0)   1.54 (1.31--1.81)   \<0.001            0.83 (0.69--1.00)    0.05
  Cancer stage                                                                                                        
   I                    70     21    37.2 (22.2--52.3)                                                                
   II                   222    61    52.4 (42.2--62.6)   0.76 (0.46--1.25)   0.29               1.03 (0.62--1.69)    0.92
   III                  393    209   29.0 (23.6--34.4)   1.3 (0.83--2.03)    0.25               1.42 (0.90--2.23)    0.13
   IV                   1077   916   10.3 (9.1--11.4)    2.9 (1.88--4.47)    \<0.001            3.85 (2.48--5.97)    \<0.001
  ECOG PS                                                                                                             
   0                    340    196   28.4 (22.7--34.1)                                                                
   1                    781    491   22.2 (19.6--24.6)   1.18 (1.0--1.40)    0.04               1.36 (1.14--1.61)    \<0.001
   2                    340    257   11.1 (8.6--13.7)    1.90 (1.58--2.29)   \<0.001            1.93 (1.59--2.34)    \<0.001
   3                    273    241   4.4 (3.2--5.6)      3.82 (3.16--4.63)   \<0.001            3.53 (2.9--4.30)     \<0.001
   4                    28     22    2.4 (0--5.7)        3.46 (2.22--5.38)   \<0.001            3.91 (2.46--6.23)    \<0.001
  TATI                                                                                                                
   High                 881    572   19.8 (17.6--22.0)                                                                
   Low                  881    635   14.0 (12.4--15.6)   1.26 (1.11--1.41)   \<0.001            1.26 (1.12--1.41)    \<0.001
  SMI                                                                                                                 
   Non-sarcopenic       998    652   19.6 (17.6--21.7)                                                                
   Sarcopenic           746    539   14.0 (12.4--15.6)   1.25 (1.12--1.40)   \<0.001            1.01 (0.9--1.14)     0.86
  Muscle radiodensity                                                                                                 
   High                 746    444   20.4 (17.5--23.3)                                                                
   Low                  998    738   13.7 (12.1--15.3)   1.41 (1.25--1.59)   \<0.001            1.33 (1.17--1.51)    \<0.001

Abbreviations: CI=confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR=hazard ratio; SMI=skeletal muscle index; TATI=total adipose tissue index.

TATI⩾107.7 cm^2^ m^−2^ in male and ⩾102.2 cm^2^ m^−2^ in females were defined as high TATI. Cut-off values for SMI and muscle radiodensity were derived from established cut-offs in gastrointestinal and respiratory cancer patients ([@bib20]). Median survival estimated using Kaplan--Meier method. HRs and *P-*values calculated using Cox proportional hazard model.

###### Median survival and mortality hazard ratios (95% CI) for (a) visceral and subcutaneous adiposity and for (b) 4-adiposity phenotypes in fully adjusted models

  **(A)**                                                        
  --------- ------ ----- ------------------- ------------------- ---------
  VATI                                                            
   High     703    462   19.7 (17.1--22.3)                        
   Low      1059   745   15.1 (13.6--16.5)   1.13 (0.99--1.28)   0.08
  SATI                                                            
   High     1068   710   19.3 (17.6--21.0)                        
   Low      694    497   13.1 (11.4--14.7)   1.26 (1.11--1.43)   \<0.001

  **(B)**                                                                   
  --------------------- ----- ----- ------------------- ------------------- ---------
  High VATI High SATI   564   377   20.4 (17.5--23.2)                        
  Low VATI Low SATI     555   412   12.6 (10.7--14.4)   1.42 (1.23--1.65)   \<0.001
  High VATI Low SATI    139   85    15.7 (12.1--19.2)   1.27 (1.00--1.62)   0.05
  Low VATI High SATI    504   333   17.6 (15.6--19.6)   1.14 (0.97--1.32)   0.13

Abbreviations: CI=confidence interval; HR=hazard ratio; SATI=subcutaneous adipose index; VATI=visceral adipose index.

Adjusted for Age, Cancer type, Stage, Performance status, Skeletal muscle index and Muscle radiodensity.

VATI⩾52.9 cm^2^ m^−2^ in male and ⩾51.5 cm^2^ m^−2^ in females were defined as high VATI. SATI⩾50 cm^2^ m^−2^ in males and ⩾42 cm^2^ m^−2^ in females were defined as high SATI. Median survival estimated using Kaplan--Meier method. HRs and *P-*values calculated using Cox proportional hazard model.

###### Characteristics of patients with high and low subcutaneous adiposity

                            **Low subcutaneous adiposity (*****n*****=694)**   **High subcutaneous adiposity (*****n*****=1068)**   ***P***
  ------------------------- -------------------------------------------------- ---------------------------------------------------- ------------------------------------
  Sex, n (%)                                                                                                                        \<0.001[a](#t4-fn3){ref-type="fn"}
   Male                     516 (74)                                           531 (50)                                              
   Female                   178 (26)                                           537 (50)                                              
  Age, years                64±12                                              64±11                                                0.68[b](#t4-fn4){ref-type="fn"}
  Cancer site, *n* (%)                                                                                                              \<0.001[a](#t4-fn3){ref-type="fn"}
   Colon/rectum             296 (43)                                           444 (42)                                              
   Respiratory tract        187 (27)                                           249 (23)                                              
   Pancreas                 70 (10)                                            74 (7)                                                
   Esophageal               14 (2)                                             9 (1)                                                 
   Stomach                  29 (4)                                             22 (2)                                                
   Other GI                 12 (2)                                             25 (2)                                                
   Kidney                   86 (12)                                            245 (23)                                              
  Cancer stage, *n* (%)                                                                                                             0.40[a](#t4-fn3){ref-type="fn"}
   I                        25 (4)                                             45 (4)                                                
   II                       81 (12)                                            141 (13)                                              
   III                      147 (21)                                           246 (23)                                              
   IV                       441 (63)                                           636 (60)                                              
  ECOG PS, *n* (%)                                                                                                                  0.70[a](#t4-fn3){ref-type="fn"}
   0                        128 (18)                                           212 (20)                                              
   1                        302 (44)                                           479 (45)                                              
   2                        141 (20)                                           199 (19)                                              
   3                        110 (16)                                           164 (15)                                              
   4                        13 (2)                                             14 (1)                                                
  BMI, kg m^−2^             22.3±3.0                                           28.2±4.9                                             \<0.001[b](#t4-fn4){ref-type="fn"}
  TATI, cm^2^ m^−2^         61.0±37.8                                          144.8±57.1                                           \<0.001[b](#t4-fn4){ref-type="fn"}
  SATI, cm^2^ m^−2^         30.4±12.6                                          85.6±38.4                                            \<0.001[b](#t4-fn4){ref-type="fn"}
  VATI, cm^2^ m^−2^         30.6±29.0                                          59.1±33.8                                            \<0.001[b](#t4-fn4){ref-type="fn"}
  SMI, cm^2^ m^−2^          45.8±8.6                                           48.1±10                                              \<0.001[b](#t4-fn4){ref-type="fn"}
  Muscle radiodensity, HU   38.7±8.4                                           31.6±9.2                                             \<0.001[b](#t4-fn4){ref-type="fn"}

Abbreviations: BMI=Body mass index; ECOG PS=Eastern Cooperative Oncology Group performance status; GI=gastrointestinal; SATI=Subcutaneous adipose index; TATI=Total adipose index; VATI=Visceral adipose index; SMI=skeletal muscle index; HU=Hounsfield unit.

Continuous variables are presented as mean±s.d.

Pearson χ2 test for categorical variables comparison.

Independent *t*-test for continuous variables.

###### Effect of sarcopenia on median overall survival in high and low visceral and subcutaneous adiposity patients

  **4-adiposity phenotypes**       **SMI**      **No. of patients**   **No. of events**   **Median survival, months (95% CI)**
  ---------------------------- ---------------- --------------------- ------------------- --------------------------------------
  High VATI                     Non-sarcopenic  359                   232                 21.8^a^ (17--26.7)
  High SATI                       Sarcopenic    200                   140                 18.5^a,e^ (13.7--23.4)
  Low VATI                      Non-sarcopenic  289                   204                 14.2^b^ (11.3--17.1)
  Low SATI                        Sarcopenic    260                   202                 10.7^c^ (8.6--12.9)
  High VATI                     Non-sarcopenic  86                    47                  22.7^a^ (16--29.4)
  Low SATI                        Sarcopenic    51                    36                  12.8^cd^ (5.7--20)
  Low VATI                      Non-sarcopenic  264                   169                 20.1^a^ (17--23.2)
  High SATI                       Sarcopenic    235                   161                 16.4^de^ (13.8--19)

Abbreviations: CI=Confidence interval; SATI=Subcutaneous adipose index; SMI=skeletal muscle index; VATI=visceral adipose index.

VATI ⩾52.9 cm^2^ m^−2^ in male and ⩾51.5 cm^2^ m^−2^ in females were defined as high VATI. SATI ⩾50 cm^2^ m^−2^ in males and ⩾42 cm^2^ m^−2^ in females were defined as high SATI. Sarcopenia was defined using Martin *et al* established cut-offs in gastrointestinal and respiratory cancer patients ([@bib20]) as values below 41 cm^2^ m^−2^ in females of all BMI categories and SMI values below 43 cm^2^ m^−2^ in male with a BMI \<25 and SMI \<53 cm^2^ m^−2^ in male with a BMI ⩾25. Different superscripts indicate significant differences (*P*\<0.05) determined by log-rank test. Median survival estimated using Kaplan--Meier method. HRs and *P-*values calculated using Cox proportional hazard model.
